GeneDx Holdings Corp. (Class A) (WGS) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
GeneDx Holdings Corp. (Class A) (WGS) surged +9.79% to $71.02, trading at 28% of its 52-week range ($32.21 – $170.87). Stretched risk/reward at current multiples (-4% return on capital) under elevated 10-year interest-rate pressure.
AI giants are planning up to US$828b in data center and chip spending this year, and that level of capital tied up in one corner of the market has many investors rethinking concentration risk. Capital that chases one sto
U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.
After the Oct. 23 US session, SHFS, CLRO and RENT led after-hours gainers, while SDST, VSME and OIS led after-hours losers.
GAITHERSBURG, Md., October 23, 2026--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quar
Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares rose 8.72% to
For questions about this article or underlying research, email help@trefis.com.
Healthcare stocks rose late Tuesday afternoon with the NYSE Healthcare Index gaining 2.2% and the St
GAITHERSBURG, Md., October 20, 2026--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with l
Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With
GAITHERSBURG, Md., October 19, 2026--GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +40.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on WGS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for WGS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, GeneDx Holdings Corp. (Class A) (WGS) ranks #224 by composite RQD confidence (58/100, grade D+) and #253 by equity capitalization ($2.12B). Within this direct 5-issuer industry benchmark cohort, ADUS leads on earnings valuation at 24.2x trailing P/E, while AVAH leads on capital efficiency and profitability with 15.7% ROIC and 33.3% gross margin. ADUS currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with WGS at 58/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| WGS
ACTIVE
GeneDx Holdings Corp. (Class A) | D+ | 58/100 | — | 69.7% | -4.1% | +9.79% | $2.12B | Benchmark Subject |
| ADUS Addus HomeCare Corporation | C+ | 69/100 | 24.2x | 32.5% | 9.1% | +1.77% | $2.32B | /adus-vs-wgs → |
| PRVA Privia Health Group Inc. | D+ | 57/100 | 122.6x | — | 10.5% | +0.71% | $2.81B | /prva-vs-wgs → |
| TDOC Teladoc Health Inc. | D+ | 56/100 | — | — | -17.0% | +26.89% | $1.59B | /tdoc-vs-wgs → |
| AVAH Aveanna Healthcare Holdings Inc. | C | 65/100 | — | 33.3% | 15.7% | +1.53% | $2.89B | /avah-vs-wgs → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), GeneDx Holdings Corp. (Class A) (WGS) reported GAAP revenue of $427.5M (+40.0% vs. FY2024 revenue of $305.4M , and +111.1% cumulative change since FY2023) , GAAP net income of -$21.0M, operating cash flow of $33.3M, and free cash flow of $14.3M (+142.0% YoY). On the balance sheet, WGS closed FY2025 with $523.7M in total assets against $48.2M in total debt (Altman Z-Score: 3.32, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $427.5M | -$21.0M | $33.3M | $14.3M | $523.7M | $48.2M |
| FY2024 (FY) | 2024-12-31 | $305.4M | -$52.3M | -$28.5M | -$34.0M | $419.4M | $51.9M |
| FY2023 (FY) | 2023-12-31 | $202.6M | -$175.8M | -$180.1M | -$180.1M | — | — |
As of 2026-11-01, GeneDx Holdings Corp. (Class A) (NASDAQ: WGS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $71.02 (+9.79% 1D, market cap $2.12B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, WGS ranks #224 in composite RQD confidence.
Within the Health Care sector (Medical/Nursing Services), WGS carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 69.7%, and ROIC of -4.1%. By comparison, ADUS (Addus HomeCare Corporation) holds a C+ grade (69/100 RQD, P/E 24.2x, ROIC 9.1%, cap $2.32B) and PRVA (Privia Health Group Inc.) posts a D+ grade (57/100 RQD, P/E 122.6x, ROIC 10.5%, cap $2.81B). Among the 5-stock peer group, ADUS leads on earnings multiple (24.2x) while AVAH leads on capital efficiency (15.7% ROIC).
Per WGS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818331), GeneDx Holdings Corp. (Class A) generated $427.5M in revenue (+40.0% YoY), -$21.0M in net income, and $14.3M in free cash flow against $523.7M in total assets and $48.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
WGS last traded at $71.02 (+9.79% on volume of 921,832 shares), positioning the stock -10.15% below its 50-day simple moving average ($79.04) and -1.27% below its 200-day simple moving average ($71.93). Across its 52-week range of $32.21 to $170.87, WGS sits at the 28.0% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($62.14 to $79.90).
Why WGS Stock surged +9.79% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-4% return on capital) under elevated 10-year interest-rate pressure.